Charles A. Schiffer

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

C. Bloomfield, E. Estey, W. Hiddemann, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

All-trans-retinoic acid in acute promyelocytic leukemia.

C. Willman, L. Shepherd, Z. Wang, 1997, The New England journal of medicine.

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

J. Radich, H. Kantarjian, D. B. Yehuda, 2013, Blood.

Clinical Observations, Interventions, and Therapeutic Trials

G. Avvisati, P. Amrein, R. Marilus, 2000 .

Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011.

R. Larson, F. Appelbaum, K. Rai, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study.

J. Neglia, H. Sather, B. Druker, 2002, Blood.

Four Years of Follow-Up of 1027 Patients with Late Chronic Phase (L-CP), Accelerated Phase (AP), or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Treated with Imatinib in Three Large Phase II Trials.

C. Sawyers, H. Kantarjian, B. Druker, 2004 .

Efficacy and morbidity of central nervous system "prophylaxis" in childhood acute lymphoblastic leukemia: eight years' experience with cranial irradiation and intrathecal methotrexate.

M. Grever, J. Belli, S. Sallan, 1983, Blood.

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

Francisco Cervantes, Ryuzo Ohno, Richard E. Clark, 2013, Blood.